629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma

Abstract

BackgroundSemaphorin4D (SEMA4D) regulates immune cell infiltration and suppressive features of myeloid cells in the tumor via engaging with receptors, PLXNB1/2 and CD72.1 In preclinical and clinical studies, SEMA4D blockade enhances...